Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 5/20 | 0.55 |
| ▸ | DBF4 | Q9UBU7 | 5/20 | 0.55 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.45 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | HPGD | P15428 | 3/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.40 |
| ▸ | BTK | Q06187 | 1/20 | 0.39 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | OGA | O60502 | 1/20 | 0.38 |
| ▸ | GABRP | O00591 | 1/20 | 0.38 |
| ▸ | GABRD | O14764 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12675085 | 0.88 | CDC7 (0.52) | CDC7DBF4HDAC3HDAC4HDAC1 | |
| SCHEMBL5755213 | 0.86 | CDC7 (0.54) | CDC7DBF4HDAC3HDAC4HDAC1 | |
| SCHEMBL18667499 | 0.82 | CDC7 (0.40) | CDC7DBF4HDAC3HDAC4HDAC1 | |
| SCHEMBL12868672 | 0.81 | HPGD (0.41) | ALDH1A1HPGDBTKP2RY1KDM4E | |
| SCHEMBL286068 | 0.80 | CDC7 (0.60) | CDC7DBF4HDAC3HDAC4HDAC1 | |
| SCHEMBL16933028 | 0.80 | CDC7 (0.60) | CDC7DBF4HDAC3HDAC4HDAC1 | |
| SCHEMBL15896622 | 0.79 | CDC7 (0.54) | CDC7DBF4HDAC3HDAC4HDAC1 | |
| SCHEMBL6476591 | 0.78 | CDC7 (0.59) | CDC7DBF4HDAC3HDAC4HDAC1 | |
| SCHEMBL274346 | 0.78 | CDC7 (0.59) | CDC7DBF4HDAC3HDAC4HDAC1 | |
| SCHEMBL14805619 | 0.77 | CDC7 (0.51) | CDC7DBF4HDAC3HDAC4HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025890-A1 | HEPATITIS B CORE PROTEIN MODULATORS | ASSEMBLY BIOSCIENCES INC (US) | 2024-01-25 | — | — | US | disclosed |
| US-20240025890-A1 | HEPATITIS B CORE PROTEIN MODULATORS | ASSEMBLY BIOSCIENCES INC (US) | 2024-01-25 | — | — | US | disclosed |
| US-20240025890-A1 | HEPATITIS B CORE PROTEIN MODULATORS | ASSEMBLY BIOSCIENCES INC (US) | 2024-01-25 | — | — | US | disclosed |
| US-11814376-B2 | Hepatitis b core protein modulators | ASSEMBLY BIOSCIENCES, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-11814376-B2 | Hepatitis b core protein modulators | ASSEMBLY BIOSCIENCES, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-11814376-B2 | Hepatitis b core protein modulators | ASSEMBLY BIOSCIENCES, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-11807644-B2 | Methods and compounds for restoring mutant p53 function | PMV PHARMACEUTICALS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-11807644-B2 | Methods and compounds for restoring mutant p53 function | PMV PHARMACEUTICALS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-20230044112-A1 | HEPATITIS B CORE PROTEIN MODULATORS | ASSEMBLY BIOSCIENCES, INC. (US) | 2023-02-09 | — | — | US | disclosed |
| US-20230044112-A1 | HEPATITIS B CORE PROTEIN MODULATORS | ASSEMBLY BIOSCIENCES, INC. (US) | 2023-02-09 | — | — | US | disclosed |
| US-8093264-B2 | Fused heterocycles as inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE INC. (CA) | 2012-01-10 | — | — | US | disclosed |
| EP-2063897-A2 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | Deciphera Pharmaceuticals, LLC. (US) | 2009-06-03 | — | — | EP | disclosed |
| US-20090048248-A1 | Octahydropyrano[3,4-C]Pyrrole Tachykinin Receptor Antagonists | MERCK SHARP & DOHME CORP. | 2009-02-19 | — | — | US | disclosed |
| US-20080255155-A1 | KINASE INHIBITORS AND USES THEREOF | METHLYGENE INC. (CA) | 2008-10-16 | — | — | US | disclosed |
| US-20080114006-A1 | Kinase inhibitors useful for the treatment of proliferative diseases | DECIPHERA PARMACEUTICALS, LLC (US) | 2008-05-15 | — | — | US | disclosed |
| WO-2008034008-A2 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | DECIPHERA PHARMACEUTICALS, LLC. (US) | 2008-03-20 | — | — | WO | disclosed |
| US-20080064718-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | METHYLGENE INC. (CA) | 2008-03-13 | — | — | US | disclosed |
| US-20080004273-A1 | Inhibitors of protein tyrosine kinase activity | METHYLGENE, INC. (CA) | 2008-01-03 | — | — | US | disclosed |
| US-20070004675-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE, INC. | 2007-01-04 | — | — | US | disclosed |
| US-20070004675-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE, INC. | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004675-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | HGF, MET, FLT1 | CDC7 869/4885DBF4 3436/4885HDAC3 1397/4885 |
| US-20240025890-A1 | HEPATITIS B CORE PROTEIN MODULATORS | HAVCR2, FABP1, MAVS | CDC7 1688/4885DBF4 945/4885HDAC3 2399/4885 |
| US-20080255155-A1 | KINASE INHIBITORS AND USES THEREOF | ABL1, MAP3K20, MAP3K1 | CDC7 168/4885DBF4 2056/4885HDAC3 2439/4885 |
| US-20230044112-A1 | HEPATITIS B CORE PROTEIN MODULATORS | HAVCR2, FABP1, MAVS | CDC7 1688/4885DBF4 945/4885HDAC3 2399/4885 |
| US-20080064718-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | HGF, ERBB2, MET | CDC7 293/4885DBF4 2981/4885HDAC3 3676/4885 |
| US-11807644-B2 | Methods and compounds for restoring mutant p53 function | TP53, TP53BP1, HRAS | CDC7 105/4885DBF4 1230/4885HDAC3 2326/4885 |
| US-11814376-B2 | Hepatitis b core protein modulators | HAVCR2, FABP1, MAVS | CDC7 1688/4885DBF4 945/4885HDAC3 2399/4885 |
| US-20090048248-A1 | Octahydropyrano[3,4-C]Pyrrole Tachykinin Receptor Antagonists | TACR1, TACR2, NPSR1 | CDC7 2744/4885DBF4 3736/4885HDAC3 2968/4885 |
| US-20080004273-A1 | Inhibitors of protein tyrosine kinase activity | HGF, ERBB2, MET | CDC7 293/4885DBF4 2981/4885HDAC3 3676/4885 |
| US-20080114006-A1 | Kinase inhibitors useful for the treatment of proliferative diseases | BRAF, PRKDC, RAF1 | CDC7 571/4885DBF4 2228/4885HDAC3 2610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.